Across
- 4. Type of real-world data source supporting upadacitinib’s efficacy regardless of biologic history.
- 5. Symptom significantly improved by upadacitinib in patients with AD.
- 11. Treatment goal evaluated when personalizing AD therapeutic dosing.
- 12. Abbreviation for the Revolutionizing Atopic Dermatitis Conference held in Nashville.
- 13. Topical JAK inhibitor in development for chronic hand eczema.
- 14. Route of administration discussed in relation to steroid withdrawal and new JAK inhibitors.
- 15. Withdrawal from this class of drugs can mimic severe AD flares.
- 16. Abbreviation used for quality of life, a key outcome improved by new AD treatments.
Down
- 1. Therapy type explored for treating chronic itch beyond type 2 inhibition.
- 2. Key to distinguishing topical steroid withdrawal from AD flares.
- 3. JAK inhibitor shown effective in moderate to severe AD after dupilumab failure in real-world data.
- 6. Country where the CAN UpTIMISE study was conducted.
- 7. Common biologic that some patients fail to respond to in AD treatment.
- 8. Therapies considered when patients present with topical steroid withdrawal signs.
- 9. Therapeutic class discussed in context of dose personalization and AD treatment.
- 10. Term used to describe the advanced approach to AD treatment tailoring.